Microbot Medical (MBOT) Competitors

Microbot Medical (NASDAQ:MBOT) and Nevro (NYSE:NVRO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, community ranking, analyst recommendations and risk.

Which has preferable earnings and valuation, MBOT or NVRO?

Microbot Medical has higher earnings, but lower revenue than Nevro. Microbot Medical is trading at a lower price-to-earnings ratio than Nevro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Microbot Medical	N/A	N/A	-$10.74M	-$0.74	-2.30
Nevro	$408.52M	0.55	-$92.21M	-$3.05	-1.91

Is MBOT or NVRO more profitable?

Microbot Medical has a net margin of 0.00% compared to Nevro's net margin of -16.54%. Nevro's return on equity of -23.52% beat Microbot Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Microbot Medical	N/A	-218.30%	-158.17%
Nevro	-16.54%	-23.52%	-10.83%

Do insiders & institutionals have more ownership in MBOT or NVRO?

16.3% of Microbot Medical shares are held by institutional investors. Comparatively, 95.5% of Nevro shares are held by institutional investors. 5.4% of Microbot Medical shares are held by company insiders. Comparatively, 3.2% of Nevro shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Does the MarketBeat Community believe in MBOT or NVRO?

Nevro received 156 more outperform votes than Microbot Medical when rated by MarketBeat users. However, 70.73% of users gave Microbot Medical an outperform vote while only 62.53% of users gave Nevro an outperform vote.

Company	Underperform	Outperform
Microbot Medical	Outperform Votes 348 70.73%	Underperform Votes 144 29.27%
Nevro	Outperform Votes 504 62.53%	Underperform Votes 302 37.47%

Which has more risk & volatility, MBOT or NVRO?

Microbot Medical has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, Nevro has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.

Does the media prefer MBOT or NVRO?

In the previous week, Microbot Medical and Microbot Medical both had 3 articles in the media. Nevro's average media sentiment score of 0.66 beat Microbot Medical's score of 0.36 indicating that Nevro is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Microbot Medical	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nevro	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer MBOT or NVRO?

Microbot Medical currently has a consensus price target of $9.00, indicating a potential upside of 429.41%. Nevro has a consensus price target of $6.43, indicating a potential upside of 10.02%. Given Microbot Medical's stronger consensus rating and higher possible upside, equities analysts plainly believe Microbot Medical is more favorable than Nevro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Microbot Medical	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Nevro	2 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.92

Summary

Microbot Medical beats Nevro on 9 of the 15 factors compared between the two stocks.